News & Updates

Show Multimedia Only

Frontline ivonescimab plus chemo ups survival in advanced squamous NSCLC

In the first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in China, the combination of ivonescimab plus chemotherapy significantly improves overall survival (OS) compared with tislelizumab plus chemotherapy, according to the phase III HARMONi-6 trial.

Frontline ivonescimab plus chemo ups survival in advanced squamous NSCLC

2 hours ago

Low-dose pembrolizumab plus chemo prolongs survival in advanced NSCLC

5 hours ago by

Adding low-dose pembrolizumab to chemotherapy results in significant improvements in overall (OS) and progression-free survival (PFS) among patients with advanced non-small cell lung cancer (NSCLC), as shown in a phase 3 trial presented at ASCO 2026.

Low-dose pembrolizumab plus chemo prolongs survival in advanced NSCLC

5 hours ago

PROTEUS sets new course for prostate cancer

6 hours ago by

In the final analysis of the phase III PROTEUS trial, perioperative apalutamide + androgen deprivation therapy (APA+ADT) improves the curative success of radical prostatectomy (RP) in men with high-risk localized or locally advanced prostate cancer (HR LPC/LAPC).

PROTEUS sets new course for prostate cancer

6 hours ago

Azithromycin of little benefit in preschool-age children with acute wheezing

10 hours ago

Azithromycin appears to only be as good as placebo in the treatment of preschool-age children presenting to the emergency department (ED) with moderate-to-severe acute wheezing, according to a study.

Azithromycin of little benefit in preschool-age children with acute wheezing

10 hours ago

Real-world data confirm effectiveness of dupilumab in eosinophilic esophagitis

22 hours ago

Dupilumab has been shown to reduce symptomatic, endoscopic, and histological eosinophilic esophagitis (EoE) markers for patients treated in routine practice, as shown in the retrospective DUPEOETALY study.

Real-world data confirm effectiveness of dupilumab in eosinophilic esophagitis

22 hours ago

One in five patients with chronic HBV infection achieves functional cure with bepirovirsen

a day ago by

The novel antisense oligonucleotide bepirovirsen has induced functional cure in one-fifth of patients with chronic hepatitis B virus (HBV) infection in the phase 3 B-Well 1 and B-Well 2 trials.

One in five patients with chronic HBV infection achieves functional cure with bepirovirsen

a day ago

$TNFi, IL-17i reduce risk of osteoporosis, but not hip fracture, in r-axSpA patients$

TNFi, IL-17i reduce risk of osteoporosis, but not hip fracture, in r-axSpA patients

a day ago

Patients with radiographic axial spondyloarthritis (r-axSpA) who have been exposed to tumour necrosis factor inhibitor (TNFi) and interleukin (IL)-17 inhibitor (IL-17i) appear to have a lower risk of osteoporosis, but not hip fracture, than biologic disease-modifying antirheumatic drug (bDMARD)-naïve individuals, a recent study has shown.

TNFi, IL-17i reduce risk of osteoporosis, but not hip fracture, in r-axSpA patients

a day ago

LNF-based regimens may alter trajectory of CHD treatment

a day ago by

Individuals with chronic hepatitis D (CHD) may benefit from lonafarnib boosted with ritonavir (LNF/RTV) alone or in combination with peg-interferon-alfa (PEG), findings from the phase III D-LIVR trial have shown.

LNF-based regimens may alter trajectory of CHD treatment

a day ago

$Lutikizumab shows promise in refractory hidradenitis suppurativa$

Lutikizumab shows promise in refractory hidradenitis suppurativa

a day ago

Treatment with lutikizumab appears to improve outcomes in patients with moderate-to-severe hidradenitis suppurativa (HS) who have not responded to anti-TNF therapy, according to a phase II trial.

Lutikizumab shows promise in refractory hidradenitis suppurativa

a day ago

Tezepelumab cuts oral corticosteroid use without compromising asthma control

09 Jun 2026 by

Tezepelumab demonstrates steroid-sparing potential in patients with severe asthma, reducing maintenance oral corticosteroid use while maintaining asthma control, as shown in the phase III SUNRISE study.

Tezepelumab cuts oral corticosteroid use without compromising asthma control

09 Jun 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Frontline ivonescimab plus chemo ups survival in advanced squamous NSCLC

Frontline ivonescimab plus chemo ups survival in advanced squamous NSCLC

Low-dose pembrolizumab plus chemo prolongs survival in advanced NSCLC

Low-dose pembrolizumab plus chemo prolongs survival in advanced NSCLC

PROTEUS sets new course for prostate cancer

PROTEUS sets new course for prostate cancer

Azithromycin of little benefit in preschool-age children with acute wheezing

Azithromycin of little benefit in preschool-age children with acute wheezing

Real-world data confirm effectiveness of dupilumab in eosinophilic esophagitis

Real-world data confirm effectiveness of dupilumab in eosinophilic esophagitis

One in five patients with chronic HBV infection achieves functional cure with bepirovirsen

One in five patients with chronic HBV infection achieves functional cure with bepirovirsen

TNFi, IL-17i reduce risk of osteoporosis, but not hip fracture, in r-axSpA patients

TNFi, IL-17i reduce risk of osteoporosis, but not hip fracture, in r-axSpA patients

LNF-based regimens may alter trajectory of CHD treatment

LNF-based regimens may alter trajectory of CHD treatment

Lutikizumab shows promise in refractory hidradenitis suppurativa

Lutikizumab shows promise in refractory hidradenitis suppurativa

Tezepelumab cuts oral corticosteroid use without compromising asthma control

Tezepelumab cuts oral corticosteroid use without compromising asthma control